118 related articles for article (PubMed ID: 18245903)
41. MiRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy.
Tong BD; Xiao MY; Zeng JX; Xiong W
Mol Vis; 2015; 21():324-34. PubMed ID: 25873777
[TBL] [Abstract][Full Text] [Related]
42. PTX3: A Potential Biomarker in Thyroid Associated Ophthalmopathy.
Mou P; Chen Z; Jiang L; Cheng J; Wei R
Biomed Res Int; 2018; 2018():5961974. PubMed ID: 29675428
[TBL] [Abstract][Full Text] [Related]
43. Quantitative Analysis of Inflammation in Orbital Fat of Thyroid-associated Ophthalmopathy Using MRI Signal Intensity.
Higashiyama T; Iwasa M; Ohji M
Sci Rep; 2017 Dec; 7(1):16874. PubMed ID: 29203853
[TBL] [Abstract][Full Text] [Related]
44. Human histocompatibility leukocyte antigen-DR and heat shock protein-70 expression in eye muscle tissue in thyroid-associated ophthalmopathy.
Hiromatsu Y; Tanaka K; Ishisaka N; Kamachi J; Kuroki T; Hoshino T; Inoue Y; Wall JR; Nonaka K
J Clin Endocrinol Metab; 1995 Feb; 80(2):685-91. PubMed ID: 7531718
[TBL] [Abstract][Full Text] [Related]
45. Orbital Fibroblasts From Graves' Orbitopathy Patients Share Functional and Immunophenotypic Properties With Mesenchymal Stem/Stromal Cells.
Brandau S; Bruderek K; Hestermann K; Görtz GE; Horstmann M; Mattheis S; Lang S; Eckstein A; Berchner-Pfannschmidt U
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6549-57. PubMed ID: 26457540
[TBL] [Abstract][Full Text] [Related]
46. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels.
Kim H; Choi YH; Park SJ; Lee SY; Kim SJ; Jou I; Kook KH
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3061-6. PubMed ID: 20053983
[TBL] [Abstract][Full Text] [Related]
47. [Gene and protein expression of thyrotropin-receptor in retro-bulbar tissue from thyroid-associated ophthalmopathy].
Sun FY; Pan Y; Song GX; Chang JW
Zhonghua Yan Ke Za Zhi; 2006 Feb; 42(2):155-8. PubMed ID: 16643732
[TBL] [Abstract][Full Text] [Related]
48. Lutein targeting orbital fibroblasts attenuates fibrotic and inflammatory effects in thyroid-associated ophthalmopathy.
Hei X; Lin B; Wu P; Li X; Mao Z; Huang S; Zhang F; Zhou M; Ke Y; Yang H; Huang D
Exp Eye Res; 2023 Jul; 232():109515. PubMed ID: 37207866
[TBL] [Abstract][Full Text] [Related]
49. COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy.
Vondrichova T; de Capretz A; Parikh H; Frenander C; Asman P; Aberg M; Groop L; Hallengren B; Lantz M
Thyroid; 2007 Jun; 17(6):511-7. PubMed ID: 17614770
[TBL] [Abstract][Full Text] [Related]
50. [Pay attention to the study on the role of orbital fatty tissue in thyroid associated ophthalmopathy].
Luo QL
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1057-9. PubMed ID: 17415959
[TBL] [Abstract][Full Text] [Related]
51. Role of macrophage infiltration in the orbital fat of patients with Graves' ophthalmopathy.
Chen MH; Chen MH; Liao SL; Chang TC; Chuang LM
Clin Endocrinol (Oxf); 2008 Aug; 69(2):332-7. PubMed ID: 18284633
[TBL] [Abstract][Full Text] [Related]
52. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
[TBL] [Abstract][Full Text] [Related]
53. Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissues from patients with thyroid-associated ophthalmopathy.
Hiromatsu Y; Sato M; Inoue Y; Koga M; Miyake I; Kameo J; Tokisawa S; Yang D; Nonaka K
Thyroid; 1996 Dec; 6(6):553-62. PubMed ID: 9001189
[TBL] [Abstract][Full Text] [Related]
54. [The pathological changes of the orbital tissue in thyroid associated ophthalmopathy].
Hei Y; Kang L; Li YY; Xiao LH
Zhonghua Yan Ke Za Zhi; 2008 May; 44(5):423-6. PubMed ID: 18953897
[TBL] [Abstract][Full Text] [Related]
55. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.
Cozma I; Zhang L; Uddin J; Lane C; Rees A; Ludgate M
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1630-5. PubMed ID: 17848636
[TBL] [Abstract][Full Text] [Related]
56. [Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].
Jiang W; Cai QY; Li ZF; Chen ZY; Luo YS; Hu SD; Shen J
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):640-645. PubMed ID: 28539287
[TBL] [Abstract][Full Text] [Related]
57. Mesenchymal Stem Cell-Like Properties of Orbital Fibroblasts in Graves' Orbitopathy.
Kozdon K; Fitchett C; Rose GE; Ezra DG; Bailly M
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5743-50. PubMed ID: 26325413
[TBL] [Abstract][Full Text] [Related]
58. The Effect of Prostaglandin Analogue Bimatoprost on Thyroid-Associated Orbitopathy.
Choi CJ; Tao W; Doddapaneni R; Acosta-Torres Z; Blessing NW; Lee BW; Pelaez D; Wester ST
Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5912-5923. PubMed ID: 30551199
[TBL] [Abstract][Full Text] [Related]
59. Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.
Chung SA; Jeon BK; Choi YH; Back KO; Lee JB; Kook KH
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2276-83. PubMed ID: 24627146
[TBL] [Abstract][Full Text] [Related]
60. Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy.
Nguyen B; Gopinath B; Tani J; Wescombe L; Wall JR
Autoimmunity; 2008 Aug; 41(5):372-6. PubMed ID: 18568642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
